OptiNose, Inc. (NASDAQ:OPTN) Shares Acquired by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA boosted its stake in OptiNose, Inc. (NASDAQ:OPTN) by 5.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,075,638 shares of the company’s stock after acquiring an additional 155,329 shares during the period. Massachusetts Financial Services Co. MA owned 2.04% of OptiNose worth $2,061,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. GSA Capital Partners LLP acquired a new position in shares of OptiNose in the 3rd quarter worth approximately $61,000. XTX Topco Ltd acquired a new position in OptiNose in the second quarter worth $88,000. Squarepoint Ops LLC boosted its holdings in OptiNose by 173.7% in the second quarter. Squarepoint Ops LLC now owns 171,610 shares of the company’s stock worth $178,000 after purchasing an additional 108,903 shares during the period. Rice Hall James & Associates LLC increased its stake in OptiNose by 15.4% during the third quarter. Rice Hall James & Associates LLC now owns 1,140,626 shares of the company’s stock valued at $764,000 after purchasing an additional 152,435 shares during the last quarter. Finally, Easterly Investment Partners LLC raised its holdings in shares of OptiNose by 5.0% during the third quarter. Easterly Investment Partners LLC now owns 2,359,239 shares of the company’s stock worth $1,581,000 after purchasing an additional 113,015 shares during the period. 85.60% of the stock is currently owned by institutional investors.

OptiNose Stock Performance

OPTN stock opened at $0.54 on Thursday. OptiNose, Inc. has a 1 year low of $0.32 and a 1 year high of $2.10. The stock has a market capitalization of $80.80 million, a price-to-earnings ratio of -1.91 and a beta of -0.07. The stock’s fifty day moving average is $0.66 and its two-hundred day moving average is $0.92.

Analyst Ratings Changes

OPTN has been the subject of several research reports. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of OptiNose in a report on Wednesday, November 13th. Piper Sandler cut their target price on shares of OptiNose from $3.00 to $1.00 and set an “overweight” rating on the stock in a report on Wednesday, November 13th.

OptiNose Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.